Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

被引:16
|
作者
Weisler, Richard H.
机构
[1] Duke Univ, Med Ctr, Durham, NC 27708 USA
[2] Univ N Carolina, Dept Psychiat, Raleigh, NC 27609 USA
关键词
atomoxetine; attention deficit hyperactivity disorder; methylphenidate; mixed amfetamine salts; psychostimulants;
D O I
10.1517/14656566.8.6.745
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A number of long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD) have recently been developed and approved for use in the US. These compounds are intended to optimize and maintain ADHD symptom control throughout the day, while eliminating problems associated with short-acting medications, such as the need for in-school, midday or multiple daily doses. Recent reports confirm that the safety and tolerability of long-acting medications are similar to those of short-acting medications, although long-acting medications appear to have a lower risk of abuse and diversion and may be associated with significant improvements in medication adherence. Distinctions can be made among the long-acting medications with regard to the onset, magnitude and duration of their clinical effects. Recognition of these differences is important for individualizing treatment for patients with ADHD.
引用
收藏
页码:745 / 758
页数:14
相关论文
共 50 条